argenx (ARGX) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incyte (INCY) has outperformed argenx (ARGX) over the past year, gaining 32.1% versus a gain of 2.5%. Over five years, ARGX leads with a +178.7% price change compared with +72.0% for INCY. argenx is the larger company by market cap ($51.88 billion vs $22.86 billion), about 2.3 times the size.
On valuation, Incyte trades at a lower forward P/E (12.9x vs 23.8x for argenx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | INCY |
|---|---|---|
| Share price | $825.03 | $112.79 |
| Market cap | $51.88B | $22.86B |
| 1-day change | +0.78% | +0.04% |
| YTD return | -2.65% | +14.15% |
| 1-year return | +2.46% | +32.06% |
| 5-year return | +178.69% | +71.98% |
| P/E ratio (TTM) | 31.44 | 14.37 |
| Forward P/E | 23.76 | 12.89 |
| EPS (TTM) | $26.24 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.14B |
| Revenue growth (YoY) | — | +21.22% |
| Net income (latest FY) | $1.29B | $1.29B |
| Gross margin | — | 92.76% |
| Operating margin | — | 29.46% |
| Net margin | — | 25.03% |
| 52-week high | $1,072.75 | $132.60 |
| 52-week low | $661.85 | $82.82 |
| Distance from 52-week high | -23.09% | -14.94% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +42.06% | +14.49% |
| Average volume | 317.26K | 1.63M |
| Shares outstanding | 62.89M | 202.70M |
| Employees | 1,863 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 2.3 times larger than Incyte by market value ($51.88B vs $22.86B).
- INCY has outperformed ARGX by 29.6 percentage points over the past year.
- argenx trades at a higher earnings multiple (31.4x vs 14.4x trailing P/E).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
ARGX vs INCY FAQ
Which is bigger, argenx or Incyte?
argenx (ARGX) is larger, with a market capitalization of $51.88B compared with $22.86B for Incyte (INCY).
Which stock has performed better over the past year, ARGX or INCY?
INCY returned +32.06% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or INCY?
INCY has the lower trailing P/E at 14.4, versus 31.4 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are argenx and Incyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for argenx and Biotechnology: Commercial Physical & Biological Resarch for Incyte.